Cadila gets EIR from USFDA for Changodar facility

NEW DELHI: Drug firm Cadila Healthcare today said it has received Establishment Inspection Report (EIR) for its Changodar manufacturing plant located near Ahmedabad from the US health regulator after successful completion of inspection.

"The company's Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016," Cadila said in a BSE filing.

It further said: "The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant".

Establishment Inspection Report is given to an establishment after the completion of the inspection by the FDA.

Last month, Cadila Healthcare had received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points" of initial review in 2014.

Cadila Healthcare shares were trading 1.23 per cent down at Rs 364.60 on BSE.